A comprehensive view of 2seventy bio Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA Advisory Committee votes in favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for triple-class exposed multiple myeloma in earlier lines of therapy
Published: March 15, 2024 by Bristol-Myers Squibb Co.
FDA to review Bristol Myers Squibb and 2seventy bio's Abecma, a CAR T cell therapy for relapsed or refractory multiple myeloma; the Oncologic Drugs Advisory Committee will assess data from the Phase 3 KarMMa-3 study in a virtual meeting
Published: February 05, 2024 by Bristol-Myers Squibb Co.
Regeneron announces formation of Regeneron Cell Medicines with the acquisition of 2seventy bio's full development and commercialization rights for novel immune cell therapies, along with discovery and clinical manufacturing capabilities
Published: January 30, 2024 by GlobeNewswire
Bristol Myers Squibb and 2seventy bio report Abecma shows a 51% reduction in disease progression or death risk for multiple myeloma patients according to data from the KarMMa-3 study; it exhibited a safety profile consistent with previous studies
Published: December 12, 2023 by Bristol-Myers Squibb Co.
Bristol Myers Squibb and 2seventy bio provide update on FDA review of sBLA for Abecma idecabtagene vicleucel in earlier lines of therapy for triple-class exposed relapsed or refractory multiple myeloma
Published: November 20, 2023 by Bristol-Myers Squibb Co.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count